Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
CAMBRIDGE, Mass., Oct. 04, 2017 -- GO Therapeutics, a company exploiting new advances in glycoproteomics to develop novel, multimodal first-in-class cancer therapeutics against intractable targets, today announced the appointment of Robert J. Wills, Ph.D. to the Company's Board of Directors. Dr. Wills is an accomplished, seasoned senior executive whose 37-year career spans directing R&D, business development and alliance management for major pharmaceutical firms and more recently in board roles for small biotechnology companies. Dr. Wills has been a Senior Advisor to the company since June 2015.
Dr. Wills is currently serving in board roles for GTx, Inc; Cymabay Therapeutics, Inc and Parion Sciences. Prior to that, Dr. Wills spent 25-years at Johnson & Johnson in a variety of senior roles in R&D and business development. Dr. Wills also worked ten-years in pharmaceutical drug development at Hoffmann-LaRoche.
"We are very pleased to have Rob join GO's Board of Directors," said Constantine Theodoropulos, Chief Executive Officer, GO Therapeutics. "As we chart GO’s growth path, we will benefit greatly from Rob’s ongoing board experience, extensive business development and R&D experience.”
Dr. Wills added, "GO Therapeutics is an exciting company that has an opportunity to play an important role in the advancement of bispecific antibodies for T cell-redirection therapy, antibody-drug conjugates, and immune-based cell therapies. I look forward to transitioning to a board role and working closely with the GO Therapeutics team to help achieve their strategic vision for the company.”
About GO Therapeutics
GO Therapeutics is applying the latest advances in glycobiology to create cancer drugs that are more potent and less toxic. GO Therapeutics’ cancer specific antibodies against tumor-specific antigens can be used in a multimodal approach to killing cancer, such as antibody-drug-conjugates, bi-specific T-cell engagers and immune-based cell therapies. The company’s scientific team includes some of the leading scientific researchers and applied biologists in glycoproteomics. GO Therapeutics is based in Cambridge, MA. For more information please visit www.gotherapeutics.com.
Constantine Theodoropulos 617-816-4637
